Search Results - "SUBRAMANIAM, DEEPA"

Recasting of Periodontal Diagnosis.

Authors: Subramaniam, Deepa Swamikannu, Bhumimathan Raghavan, R. Narasimha et al.

Source: Journal of Pharmacy & Bioallied Sciences. 2025 Suppl 3, Vol. 17, pS2060-S2066. 7p.

Biphasic Calcium Phosphate in the Extraction Socket Preservation: A Systematic Review.

Authors: S., Mohanasatheesh Balaji, Anitha Subramaniam, Deepa et al.

Source: Journal of Pharmacy & Bioallied Sciences. 2024 Supplement, Vol. 16, pS1007-S1011. 5p.

Surgical Excision of Hypertrophic Tissue and Retrieval of Orthodontic Mini-implant using Diode Laser-A Rare Case Report.

Authors: IDA, EVANGELINE RAMYA, V. BALAJI, ANITHA et al.

Source: Journal of Clinical & Diagnostic Research. Aug2023, Vol. 17 Issue 8, p1-3. 3p.

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.

Authors: Trivedi, Neel D. Armstrong, Samantha Wang, Hongkun et al.

Source: Cancer Medicine. Mar2021, Vol. 10 Issue 6, p1944-1954. 11p.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.

Authors: Wakelee, Heather Gettinger, Scott Engelman, Jeffrey et al.

Source: Cancer Chemotherapy & Pharmacology. May2017, Vol. 79 Issue 5, p923-932. 10p.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Authors: Deeken, John F. Wang, Hongkun Subramaniam, Deepa et al.

Source: Cancer (0008543X). May2015, Vol. 121 Issue 10, p1645-1653. 10p.

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Authors: Crandall, John Tahari, Abdel Juergens, Rosalyn et al.

Source: EJNMMI Research. 1/19/2017, Vol. 7 Issue 1, p1-10. 10p.

CyberKnife for hilar lung tumors: report of clinical response and toxicity.

Authors: Unger, Keith Ju, Andrew Oermann, Eric et al.

Source: Journal of Hematology & Oncology. 2010, Vol. 3, p39-45. 7p.

CyberKnife® enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.

Authors: Oermann, Eric Collins, Brian T. Erickson, Kelly T. et al.

Source: Journal of Hematology & Oncology. 2010, Vol. 3, p22-30. 9p.

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.

Authors: Reardon, David A. Kim, Tae Min Frenel, Jean‐Sebastien et al.

Source: Cancer (0008543X). May2021, Vol. 127 Issue 10, p1620-1629. 10p.

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Authors: Lynce, Filipa Wang, Hongkun Petricoin, Emanuel F. et al.

Source: Cancer Chemotherapy & Pharmacology. Nov2019, Vol. 84 Issue 5, p1145-1151. 7p.

Dramatic Response to Sequential BRAF Inhibition in BRAF V600E–Mutant Metastatic Lung Adenocarcinoma.

Authors: Jonna, Sushma Giaccone, Giuseppe Filice, Ross et al.

Source: JCO Precision Oncology. 11/27/2018, Vol. 2, p1-6. 6p.

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

Authors: Berlin, Jordan Ramanathan, Ramesh K. Strickler, John H. et al.

Source: British Journal of Cancer. Apr2018, Vol. 118 Issue 7, p938-946. 9p. 1 Diagram, 3 Charts, 2 Graphs.

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

Authors: Giaccone, Giuseppe Kim, Chul Thompson, Jillian et al.

Source: Lancet Oncology. Mar2018, Vol. 19 Issue 3, p347-355. 9p.

Electromagnetic fields alter the motility of metastatic breast cancer cells.

Authors: Garg, Ayush Arpit Jones, Travis H. Moss, Sarah M. et al.

Source: Communications Biology. 8/8/2019, Vol. 2 Issue 1, pN.PAG-N.PAG. 1p.

Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

Authors: Villalona‐Calero, Miguel A. Lam, Elaine Otterson, Gregory A. et al.

Source: Cancer (0008543X). Mar2016, Vol. 122 Issue 6, p875-883. 9p.

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.

Authors: Kang-Seo Park Raffeld, Mark Yong Wha Moon et al.

Source: Journal of Clinical Investigation. Jul2014, Vol. 124 Issue 7, p3003-3015. 13p. 6 Color Photographs.

A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Authors: Deeken, John Slack, Rebecca Weiss, Glen et al.

Source: Cancer Chemotherapy & Pharmacology. Mar2013, Vol. 71 Issue 3, p627-633. 7p.

Pulmonary Function Tests One Year Following Robotic Radiosurgery for High-Risk Surgical Patients With Stage I Non-small Cell Lung Cancer.

Authors: Casey, Daniel Oermann, Eric Chen, Viola et al.

Source: CHEST. Oct2011 Supplement, Vol. 140, p317A-317B. 1p.

Robotic Radiosurgery for Hilar Lung Tumors: Report of Local Control and Survival.

Authors: Unger, Keith Ju, Andrew Oermann, Eric et al.

Source: CHEST. Oct2010 Supplement, Vol. 138, p262A-262A. 1p.